Introduction: The glucagon-like peptide-1 (GLP-1) receptor agonist class has grown in the
INTRODUCTION
Type 2 diabetes mellitus is a complex and progressive disease that is associated with a significant clinical and economic burden globally. Currently 415 million people have diabetes worldwide, with type 2 diabetes representing approximately 90% of cases, and it is estimated that this will rise to 642 million in 2040 [1] . In the United Kingdom (UK) the prevalence of diabetes is 6.2%, with 3.3 million diagnosed patients [2] . In 2013, over 50,000 hospital admissions and approximately 5000 deaths were attributable to the disease. Across the UK, one in seven hospital beds is occupied by a patient with diabetes, and in some hospitals this can be as high as 30% of beds [3] . People with diabetes are at twice the risk of experiencing a cardiovascular event during their lifetime compared with the general population, and diabetes is the most common cause of renal failure (the primary cause in over 25% of patients) [4, 5] . The risk of micro-and macrovascular complications can be reduced through maintaining glycemic control and managing other risk factors such as body weight, hypertension and hyperlipidemia [6] [7] [8] .
Diabetes is also associated with a significant economic burden in the UK, with type 2 diabetes comprising the majority of this. In 2011 the annual direct cost of type 2 diabetes was estimated to be GBP 8.8 billion, with indirect costs of GBP 13 billion. It is projected that direct and indirect costs will increase to GBP 15.1 billion and GBP 20.5 billion, respectively, by 2035 [9] . It has been estimated that drug costs make up less than 10% of the total cost burden of diabetes in the UK and that the predominant driver of the economic burden is diabetes-related complications [9] .
The glucagon-like peptide-1 (GLP- The GLP-1 receptor agonists act through activation of the GLP-1 receptor, which is present within a number of tissues, resulting in a range of physiological effects. These include stimulation of glucose-dependent insulin secretion, inhibition of glucagon release, delaying gastric emptying, and increasing satiety [10, 11] . This broad mechanism of action gives the GLP-1 receptor agonists a number of favorable treatment characteristics. As well as improved glycemic control, GLP-1 receptor agonists are associated with weight loss, reductions in blood pressure, and low risk of hypoglycemia [10, 11] . This has been shown to result in long-term benefits, with data from the randomized, suggested that exenatide may be associated with a reduced risk of cardiovascular events than other treatment options [12, 13] .
While numerous studies have been conducted that have compared GLP-1 receptor agonists with other therapy options such as sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 inhibitors, and insulin glargine, only three published studies have directly compared daily administered GLP-1 receptor agonists for a period greater than 24 weeks [14] [15] [16] [17] [18] [19] [20] [21] [22] . The Liraglutide Effect and Action in Diabetes 6 (LEAD-6) trial (NCT00518882) compared liraglutide 1.8 mg with exenatide 10 lg BID in patients with type 2 diabetes failing to achieve glycemic targets on metformin and/or sulfonylurea [20] . Liraglutide 1.8 mg reduced mean glycated hemoglobin (HbA1c) significantly more than exenatide 10 lg BID (estimated treatment difference -0.33; 95% confidence interval -0.47 to -0.18; p\0.0001), and more patients receiving liraglutide achieved an HbA1c target of \7% (54% versus 43%, respectively). Both liraglutide 1.8 mg and exenatide 10 lg BID were associated with similar weight loss (-3.24 and -2.87 kg, respectively). Rates of hypoglycemia were low in both treatment arms, but liraglutide 1.8 mg was associated with a statistically significant reduction in minor hypoglycemic events (1.93 versus 2.60 events per patient per year; p = 0.0131). Liraglutide 1.8 mg and lixisenatide 20 lg were compared in patients with type 2 diabetes not meeting glycemic targets on metformin monotherapy in the LIRA-LIXI trial (NCT01973231) [22] . Liraglutide 1.8 mg was associated with a greater reduction in HbA1c (estimated treatment difference -0.62%; 95% confidence interval -0.80% to -0.44%; p\0.0001) and greater proportions of patients achieving HbA1c targets of \7% and B6.5%.
Both interventions were associated with similar reductions in blood pressure and body weight, and had similar safety profiles.
The GetGoal-X study (NCT00707031) compared lixisenatide 20 lg with exenatide 10 lg BID in patients with type 2 diabetes failing to achieve glycemic control on metformin monotherapy [21] . The two therapies were found to be comparable, with lixisenatide 20 lg found to be non-inferior to exenatide 10 lg BID in The aim of the present analysis was to explore this area further and to compare the long-term cost-effectiveness of currently available daily administered GLP-1 receptor agonists for which there is no head-to-head trial evidence. The study evaluated the cost-effectiveness of liraglutide 1.2 mg, exenatide 10 lg BID and lixisenatide 20 lg, for treatment of patients with type 2 diabetes in the UK setting based on the results of a network meta-analysis [23] .
METHODS

Model Description
The analysis was performed using the IMS CORE [32] .
Simulated Cohort
The baseline cohort of the analysis was based on the LEAD-6 trial, a 26-week, open-label, parallel-group study comparing liraglutide 1.8 mg once daily with exenatide 10 lg BID [20] .
Participants were eligible to take part if they had type 2 diabetes with HbA1c of 7-11%, were aged 
Estimation of Treatment Effects
The study aimed to assess the cost-effectiveness of daily administered GLP-1 receptor agonists where there is currently no head-to-head trial evidence (liraglutide 1.2 mg, exenatide 10 lg BID and lixisenatide 20 lg). Clinical data were taken, therefore, from a network meta-analysis of 13 randomized, controlled trials evaluating the efficacy and safety of daily administered GLP-1 receptor agonists for the treatment of insulin naïve patients with type 2 diabetes [23] .
Change from baseline in HbA1c, BMI and systolic blood pressure were taken from the network meta-analysis. For each of the therapies, the network meta-analysis provided the mean differences in each parameter, versus each of the other therapies. Therefore to calculate the treatment effects to be applied in the modeling analysis, these differences were applied to a reference treatment. Treatment differences versus liraglutide 1.8 mg identified in the network meta-analysis (Table 1) were applied to the liraglutide 1.8 mg arm of the LEAD-6 study to give the treatment effects applied in the first year of the analysis in each of the treatment arms (Table 2) . No data were available to inform the systolic blood pressure change in the lixisenatide 20 lg arm and therefore this was matched to the liraglutide 1.2 mg arm. This is likely to be a conservative approach as liraglutide 1.2 mg was associated with a greater reduction in systolic blood pressure than exenatide 10 lg BID, and therefore in the absence of data for lixisenatide 20 lg the most favourable change was assumed. Moreover, it is likely that the alternative GLP-1 receptor agonists are associated with comparable reductions in systolic blood pressure [33, 34] . Liraglutide 1.2 mg was associated with a statistically significant reduction in HbA1c compared to exenatide 10 lg BID and lixisenatide 20 lg, but differences in systolic blood pressure and BMI were not statistically significant.
Treatment Intensification and Long-term Parameter Progression
Patients were assumed to receive GLP-1 receptor agonist therapy for 3 years before intensifying to receive neutral protamine Hagedorn (NPH)
insulin for the remainder of the simulation. This assumption recognizes that intensification to basal insulin will be required to maintain glycemic control, and is in line with previously published cost-effectiveness analyses and submissions to the National Institute for Health and Care Excellence (NICE) [24, 35] .
Alternative assumptions around treatment switching were tested in sensitivity analyses (see below). (Table 3) were identified through literature review, with costs inflated to 2015 values using the Hospital and Community Health Services price index were necessary [36] .
Health-related quality of life utilities associated with diabetes-related complications were derived from previous cost-effectiveness evaluations of GLP-1 receptor agonists carried out in the UK setting (Table 4 ) [24, 25] .
Sensitivity Analyses
A number of sensitivity analyses were conducted to identify key drivers of outcomes in the base case analysis. The influence of time horizon on the model outcomes was assessed by running the analyses over 20 years. It should be noted that this analysis does not capture all long-term outcomes, as not all patients were dead at the end of the simulation. The effect of discount rates on future costs and clinical outcomes was investigated through analyses in which they were set (symmetrically) to 0% and 6% per annum, in line with guidance for the UK setting [32] . based on a review of prescription data [38] .
Compliance with Ethics Guidelines
This article does not contain any new studies with human or animal subjects performed by any of the authors.
RESULTS
Base Case Analysis
The base case analysis found that liraglutide 1.2 mg was associated with benefits in life expectancy and quality-adjusted life expectancy versus other daily administered GLP-1 receptor agonists, at 13.73 years and 9.19 quality-adjusted life years (QALYs), respectively (Table 5 ). Lixisenatide 20 lg was associated with the lowest life expectancy (13.67 years) and quality-adjusted life expectancy (9.12 QALYs). Differences between the three therapy arms resulted from differences in the cumulative incidence of end-stage diabetes-related complications, driven by differences in glycemic control. Liraglutide 1.2 mg was associated with the lowest cumulative incidence of microvascular and macrovascular diabetes-related complications, followed by exenatide 10 lg BID, followed by lixisenatide 20 lg (Fig. 1) . 
Sensitivity Analyses
Sensitivity analyses identified that the key driver of improved clinical outcomes with liraglutide 1.2 mg was a greater reduction in HbA1c than with exenatide 10 lg BID and lixisenatide 20 lg (Table 6 ). Abolishing the Myocardial infarction, year of event -0.129 [51] Myocardial infarction, years 2? 0.736 [51] Angina 0.682 [51] Congestive heart failure 0.633 [51] Stroke, year of the event -0.181 [51] Stroke, years 2? 0.545 [51] Peripheral vascular disease 0.57 [52] Microalbuminuria 0.814 [51] Gross proteinuria 0.814 [51] Hemodialysis 0.490 [52] Peritoneal dialysis 0.560 [52] Renal transplant 0.762 [52] Background diabetic retinopathy 0.814 [51] Background Clinical outcomes were stable when alternative assumptions around treatment switching were evaluated, but cost outcomes were sensitive to changes. Assuming that patients receiving insulin glargine rather than NPH insulin resulted in only minor changes in the incremental cost outcomes, and the conclusions of the analyses did not change. A further limitation of the present analysis is the reliance on short-term data in making long-term predictions of outcomes over time horizons of up to 50 years. However, this is a limitation inherent to most cost-effectiveness modeling studies and, despite this, such studies represent one of the best available options for making estimates of long-term clinical and economic outcomes in the absence of long-term clinical data. As a result there is unavoidable uncertainty around how well the modeling analysis represents the real world. The present study aims to minimize this limitation, through use of a recently validated model, which has been accepted by a number of reimbursement authorities, to conduct the analysis and by conducting extensive sensitivity analyses to examine the effects of alternative inputs on long-term projections [31] .
CONCLUSIONS
The present study represents the first long-term cost-effectiveness analysis of alternative daily 
